Skip to content
Riskpilot
← Back to search
Sign in
Sign in
Get full access
Moberg Pharma AB (publ)
AB
Active
Org 5566977426
Gustavslundsvägen 42, 167 51
Bromma
Research and experimental development on natural sciences and engineering
·
NACE 7210
Est. 2006 · 20 years old
5-9 employees
Monitor
Share
Sweden
/
Companies
/
Research and experimental development on natural sciences and engineering
/
Moberg Pharma AB (publ)
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
SEK millions
62M
47M
31M
16M
0M
2019: 43M
43M
2019
2020: 50M (+16% vs 2019)
50M
+16%
2020
2021: 0M (-100% vs 2020)
0M
-100%
2021
2022: 0M
0M
2022
2023: 0M
0M
2023
EBITDA
SEK millions
30M
11M
-9M
-28M
-47M
2019: -32M
-32M
2019
2020: 15M (+147% vs 2019)
15M
+147%
2020
2021: -20M (-233% vs 2020)
-20M
-233%
2021
2022: -20M (0% vs 2021)
-20M
0%
2022
2023: -27M (-35% vs 2022)
-27M
-35%
2023
Income statement
SEK thousands
Item
2023
2022
2021
2020
2019
Revenue
0
207
0
50 488
42 848
Staff expenses
—
—
—
—
—
EBITDA
−27 463
−20 226
−19 521
14 826
−31 639
Depreciation & amort.
—
—
—
—
—
EBIT
−27 463
−20 226
−19 521
14 826
−31 639
Net financials
2 043
714
−240
−3 575
574 612
Profit before tax
−25 420
−19 512
−19 761
12 251
572 522
Tax
4 327
3 802
3 703
−2 976
6 553
Net profit
−21 093
−15 710
−16 058
9 275
579 075
Balance sheet
SEK thousands
Item
2023
2022
2021
2020
2019
Total assets
634 832
564 523
450 989
514 080
1 210 072
Equity
610 726
533 585
434 052
449 632
1 121 030
Long-term debt
3 467
4 053
1 300
4 818
32 038
Short-term debt
20 639
26 885
15 637
59 630
57 005
Total debt
24 106
30 938
16 937
64 448
89 043
Financial ratios
5-year trend
EBITDA margin
<−999 %
This company
15,8 %
Market median
This company
Market median
>999% below market
2019
2023
Equity ratio
96,2 %
This company
38,2 %
Market median
This company
Market median
152% above market
2019
2023
Return on equity
−3,5 %
This company
18,4 %
Market median
This company
Market median
119% below market
2019
2023
Net profit margin
<−999 %
This company
8,1 %
Market median
This company
Market median
>999% below market
2019
2023
Asset turnover
0,00×
This company
1,12×
Market median
This company
Market median
100% below market
2019
2023
Debt / equity
0,04×
This company
0,62×
Market median
This company
Market median
94% below market
2019
2023
Annual reports & filings
Annual report 2023
Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
View
PDF
Annual report 2020
Filed via Bolagsverket / SCB · Period 2019-07-01 – 2020-12-31
View
PDF
Annual report 2019
Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-06-30
View
PDF
More on Moberg Pharma AB (publ)
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
